Clonal Hematopoiesis From Next Generation Sequencing of Plasma From a Patient With Lung Adenocarcinoma: A Case Report

Munehiro Ito¹, Yutaka Fujiwara¹,²,³*, Takashi Kubo⁴, Hiromichi Matsushita⁵, Tadashi Kumamoto⁶, Tatsuya Suzuki⁷, Kuniko Sunami⁵, Noboru Yamamoto¹,² and Takashi Kohno⁴,⁸

¹Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan, ²Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, ³Department of Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan, ⁴Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan, ⁵Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan, ⁶Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan, ⁷Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, ⁸Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan

Reliable and accurate next generation sequencing (NGS) technologies are important in precision medicine. Analysis using currently available NGS genomic tests is conducted on cancer-derived DNA collected from tumor tissue, blood, or both. Clonal hematopoiesis (CH) produces a detectable somatic clonal mutation that is commonly associated with clonal expansion of hematopoietic cells with age and genomic analysis of blood samples can be used to detect CH. A 74-year-old Korean male had lung adenocarcinoma with a metastasis to the left scapula. He underwent palliative radiotherapy to the left scapula and received multi-line chemotherapies. After disease progression, he underwent re-biopsy of the metastatic tumor tissue from lung cancer and concomitant blood sampling. NGS genomic testing revealed no significant genomic mutation in the tumor tissue DNA but showed the $TP53$ mutation C135Y in peripheral blood DNA. To investigate the discordance between the genotyping results in tumor tissue and blood, we tested for the $TP53$ mutation using a target sequencing test in blood and normal oral mucosa. The $TP53$ mutation C135Y was only detected in the blood sample, confirming the presence of $TP53$-mutated CH. We should be aware of different characteristics in NGS genomic testing including sample type such as tumor, blood, or paired specimens. Performing genomic testing on paired tumor and blood samples is effective for discriminating mutations derived from CH from germline mutations and somatic mutations in tumor cells.

Keywords: cell-free DNA, clonal hematopoiesis, next generation sequencing, precision medicine, TP53 mutation

**BACKGROUND**

Precision medicine is an emerging approach for providing patient-specific treatment based on genomic data using next generation sequencing (NGS). Reliable and accurate NGS technologies are essential in precision medicine (1). Several commercial genomic tests are available (Table 1). Each of these tests has different characteristics including the sequencing system; the number...
of tested genes; sample type such as tumor, blood, or paired specimens; and the curation and annotation system.

| Platform          | Target          | Sample type                  | Genes tested | Turnaround time | Approval               |
|-------------------|-----------------|------------------------------|--------------|-----------------|------------------------|
| NCC-Oncopanel     | Solid tumor     | Tumor (FFPE) and blood (control) | 114 genes    | –               | Japan-approved         |
| MSK-IMPACT        | Solid tumor     | Tumor (FFPE) and blood (control) | 468 genes    | 21 days         | FDA-approved           |
| Guardant360       | Solid tumor     | Blood (cfDNA)                | 73 genes     | 7 days          | –                      |
| FoundationOne CDx | Solid tumor     | Tumor (FFPE)                 | 324 genes    | Within 14 days  | FDA and Japan-approved |

FFPE, formalin fixation and paraffin embedding; cfDNA, cell-free DNA.

Clonal hematopoiesis (CH) produces a detectable somatic clonal mutation that is commonly associated with clonal expansion of hematopoietic cells with age (6). As the use of NGS analysis has increased, studies have reported some discordances between genotyping results from tumor tissue and plasma specimens, which may be caused by tumor heterogeneity, variable shedding of tumor DNA into the plasma, and/or CH (7, 8). Here, we report a case of TP53-mutated CH in a patient with lung adenocarcinoma.

**CASE PRESENTATION**

A 74-year-old Korean man was referred to us for lung adenocarcinoma with left scapula metastasis. He had a normal complete blood count and no family history of malignant disease. Following palliative radiotherapy to the scapula, he had been treated with multi-line chemotherapies. However, his scapula metastasis had progressed. He provided written informed consent to undergo genomic testing. Undecalcified tumor tissue of the scapula metastasis from lung adenocarcinoma and a blood sample were submitted for NGS genomic testing using
marker of response to cetuximab therapy in colorectal cancer

TABLE 2: Results of genomic tests in a patient with TP53-mutated CH.

| Testing | Sample      | Fresh or archived | Mutation | Results                                      |
|---------|-------------|-------------------|----------|----------------------------------------------|
| 1st     | Tumor Blood | Archived Fresh    | No mutation | Discordance between tumor and blood specimens |
|         |             |                   | TP-53 mutation |                                             |
| 2nd     | Oral mucosa Blood | Fresh Fresh | No mutation | Discordance between oral mucosa and blood specimens |
|         |             |                   | TP-53 mutation C135Y, c404G>A (p.Cys135Tyr) |                                             |

CH, clonal hematopoiesis.

NCC-Oncopanel test, which was developed at the National Cancer Center in Japan. Testing of the blood sample detected a TP53 mutation (C135Y, c404G>A [p.Cys135Tyr], allele frequency 29.8%), but there was no matching mutation in the tumor tissue (Figure 1). The criteria for myelodysplastic syndromes (MDS), Waldenström macroglobulinemia, IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), and Li-Fraumeni syndrome were not met. We suspected CH as the cause of the discordance between findings in tumor tissue and blood. We therefore verified the presence of the TP53 mutation with a TP53 target sequencing test using the sequencing by synthesis method (Falco Holdings Co., Ltd.) in blood and normal oral mucosa. The TP53 mutation C135Y was only detected in the blood (Table 2).

DISCUSSION AND CONCLUSIONS

CH is an aging-related phenomenon in which hematopoietic stem cells or other early blood cell progenitors contribute to the formation of a genetically distinct subpopulation of blood cells (6). CH is considered to be associated with prior exposure to chemotherapy or irradiation in cancer patients as well as increased age (10). Plasma cell-free DNA genotyping detected that some mutations such as JAK2, TP53, and KRAS can be derived from CH and not from cancer (7).

The cause of the genotyping discordance between tumor tissue and blood is important for determining the treatment strategy. Although the TP53 mutation is not targetable, germline TP53 mutations result in a hereditary condition known as Li-Fraumeni syndrome and the KRAS mutation is a predictive marker of response to cetuximab therapy in colorectal cancer (11, 12). CH detected from cell-free DNA can cause misdiagnosis of the mutation origin and complicate the treatment strategy (7, 8). Pairing of plasma and tumor genomic tests is important, although paired sample testing is expensive.

We report a case of TP53-mutated CH in a lung adenocarcinoma patient in which target sequencing was used to confirm mutations derived from CH.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Genomic profiling study (The TOP-GEAR study) was registered at UMIN Clinical Trials Registry (UMIN 000011141) and approved by Institutional Review Board at National Cancer Center Hospital on June 27th, 2013. The patients/participants provided their written informed consent to participate in this study.

CONSENT FOR PUBLICATION

This patient provided written informed consent to participate in TOP-GEAR study. The authors have obtained consent from the patient for publication of this case report.

AUTHOR CONTRIBUTIONS

MI and YF drafted the manuscript. YF contributed to the management of the clinical case. MI, YF, TKub, HM, TKum, TS, KS, NY, and TKo reviewed the manuscript and participated in clinical data interpretation. All authors read and approved the final manuscript.

FUNDING

This study was supported by the Japan Agency for Medical Research and Development (AMED) (17lk1403003h0001 and 18lk1403003h0002) and National Cancer Center Research and Development Fund (30-A-6, and NCC Biobank).

ACKNOWLEDGMENTS

The authors would like to thank all the medical staff who were involved in the care of the patient and the staff of NCC-Oncopanel. We thank Libby Cone, MD, MA, from DMC Corp. (www.dmed.co.jp) for editing drafts of this manuscript.

REFERENCES

1. Kuderer NM, Burton KA, Blau S, Rose AL, Parker S, Lyman GH, et al. Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol. (2017) 3:996–8. doi: 10.1001/jamaoncol.2016.4983
2. Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci. (2019) 110:1480–90. doi: 10.1111/cas.13969
3. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. (2017) 23:703–13. doi: 10.1038/nm.4333
4. Guardant Health. Guardant 360. (2019). Available online at: http://www.guardant360.com (accessed October 5, 2019).
5. Foundation Medicine. FoundationOne CDx. (2019). Available online at: https://www.foundationmedicine.com/genomic-testing/foundation-one-cdx (accessed October 5, 2019).
6. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. (2014) 371:2477–87. doi: 10.1056/NEJMoa1409405
7. Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, et al. False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res. (2018) 24:4437–43. doi: 10.1158/1078-0432.CCR-18-0143
8. Coombs CC, Gillis NK, Tan X, Berg JS, Ball M, Balasis ME, et al. Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. Clin Cancer Res. (2018) 24:5918–24. doi: 10.1158/1078-0432.CCR-18-1201
9. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. (2011) 29:24–6. doi: 10.1038/nbt.1754
10. Coombs CC, Zehir A, Devlin SM, Kishatgar A, Syed A, Jonsson P, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. (2017) 21:374–82.e4. doi: 10.1016/j.stem.2017.07.010
11. McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol. (2014) 11:260–71. doi: 10.1038/nrclinonc.2014.41
12. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JE, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. (2006) 66:3992–5. doi: 10.1158/0008-5472.CAN-06-0191

Conflict of Interest: YF reports speaker’s bureau from Sysmex. NY is a recipient of a research grant from Japan Agency for Medical Research and Development (AMED, 17lk1403003h0001, and 18lk1403003h0002). KS and TKo are recipients of a collaborative research grant from the Sysmex Corporation.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Ito, Fujiwara, Kubo, Matsushita, Kumamoto, Suzuki, Sunami, Yamamoto and Kohno. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.